Can We Do Better? Current & Future Realities of mRNA Process Development

There’s been great progress in establishing processes and platforms for linear mRNA vaccines — but where does this current know-how fall short for those exploring linear and next-gen RNA constructs for therapeutic (non-vaccine) products? This Advancing RNA Live panel discussion dug into the current known unknowns (and unknown unknowns) about our mRNA therapeutics candidates that make adopting the traditional QbD approach complicated in the mRNA therapeutics space today.

We unpacked how companies can best navigate an evolving R&D landscape and an immature analytical paradigm while working internally and/or with CDMO partners to confidently answer the question, “What actually is good enough?” as it relates to our therapeutics’ process development.

Available on-demand thanks to the support of Roche CustomBiotech.

Don't have time to watch the full video? Check out these segments by topic:

• The Evolutions Of mRNA Analytical Development (So Far)
• How Analytical Development Is Informing mRNA Process Development Today
• The State Of CircRNA Analytical Development
• A Double-Edged Sword? Defining "Efficiency" In mRNA Process Development
• Is QBD Actually Possible In mRNA Development Today?
• How Can Sponsors & CDMOs Collaborate On RNA Analytical/Process Development?
• Don't Forget These Important Points When Selecting An RNA CDMO